Showing results (81-90 of 185) with videos related to
Sort By:
Pageof 19
Clinical Transplantation|July 27, 2020
Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantationPinar Ataca Atilla, Erman Akkus, Erden Atilla, et al.Oncology and Therapy|March 26, 2026
Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature ReviewMeral Beksac, Mohamed Samra, Omar Abduljalil, et al.Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|March 26, 2026
Allogeneic Hematopoietic Cell Transplantation for Relapsed / Refractory Hodgkin Lymphoma: A Multicenter Real-World ExperienceDerya Koyun, Uğur Şahin, Güldane Cengiz Seval, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 6, 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myelomaMaria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, et al.Antiviral Therapy|July 5, 2018
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?Erden Atilla, Merih Yalciner, Pinar Ataca Atilla, et al.Blood Cancer Journal|November 28, 2024
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studiesPaul G Richardson, Aurore Perrot, Joseph Mikhael, et al.British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialMeletios A Dimopoulos, Ivan Špička, Hang Quach, et al.The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.Pageof 19